Galderma delivered net sales of 4.765 billion USD in the first nine months of 2026, raising our full-year sales guidance.

Read more: galderma.com/news/galderma-…

#AdvancingDermatology #Q3results $GALD

We’re excited to share that the Chinese NMPA has approved our next-generation anti-wrinkle treatment, designed with PEARL™ Technology, for the improvement of frown lines in adults.

Learn more: galderma.com/galderma-relfy…

#AdvancingDermatology
#SkinSciencebyGalderma
#ForInvestors

Join Galderma’s analyst call today at 15:30 CET as we discuss our record-breaking Q3 results.

Access the live call here: investors.galderma.com/events-present…

A recording will be available after the event.
#AdvancingDermatology #Q3results $GALD

We’re glad to share that Sculptra® – the first proven regenerative biostimulator – has been approved for use on the body in the United Arab Emirates.

#HCPs can learn more at a symposium at AMWC Dubai tomorrow.

Find out more: bit.ly/4yrOvEF

#AdvancingDermatology

At #AMWCDubai Galderma will showcase data across Sculptra®, Restylane® and our neuromodulator portfolio, reinforcing our Injectable Aesthetics leadership.

galderma.com/news/amwc-duba…

#AdvancingDermatology #SkinSciencebyGalderma

57% of women feel anxious from menopause-related skin changes, which can have negative effects on wellbeing.

On #WorldMenopauseDay, we’re ensuring that women feel good in their skin through every life stage.
#RewriteTheFutureOfYourSkin

Learn more: galdermaaesthetics.com/menopause

Galderma shares phase II patient-reported outcomes of its atopic dermatitis treatment being investigated for use in children aged 2 to 11.

Read more galderma.com/news/pedra-202…

#ForInvestors

@pedra Research

Galderma signs agreement to acquire ZO Skin Health, strengthening its physician-dispensed skincare offering
galderma.com/news/galderma-…

Galderma releases latest menopause patient research findings: over half of women say they first put menopause-related skin changes down to aging.

Less than a third recognized menopause as the cause.

Find out more galderma.com/news/the-menop…

#AdvancingDermatology
#Menopause

Galderma will present new post-hoc results from a long-term extension study of our #atopicdermatitis treatment at the #FallClinical Dermatology Conference this weekend.

Learn more: galderma.com/news/fall-clin…

@dermsquared
#ForInvestors

Over 50% of women learn about menopause-related skin changes by living through them.

At Galderma, we’re raising awareness about the impact of menopause on the skin so women can feel their best during this life transition.

Learn more here: galderma.com/news/aesthetic…

Celebrating 30 years of Restylane®.

From the first HA injectable to market, to three pioneering technologies shaping aesthetic medicine.

Here's to 30 years of innovation. galderma.com/news/30-years-…

#SkinSciencebyGalderma #AdvancingDermatology

We are unveiling new three-year long-term data in atopic dermatitis at @EADV_ 2026 in Vienna.

Learn more: galderma.com/news/eadv-2026…

#ForInvestors #SkinScienceByGalderma
#EADVCongress

We are thrilled to be attending the @EADV_ congress in Vienna next week!

Learn more about how we’re helping to shape the future of skin health at #EADVCongress: galderma.com/news/eadv-2026…

#ForHCPs

#AdvancingDermatology #SkinScienceByGalderma

New clinical data from China show that Restylane® Volyme™ is highly effective in the correction of moderate-to-severe temple hollowing, while also achieving high patient and investigator satisfaction.

Read more: galderma.com/news/galderma-…

#SkinSciencebyGalderma

A new home for our next chapter in the Americas.
Galderma has officially opened its U.S. and Latin America headquarters in Miami — strengthening collaboration and building on our continued investment in U.S. growth.
Read more galderma.com/news/galderma-…
#AdvancingDermatology

Join Galderma’s analyst call today at 13:00 CEST as we discuss our record-breaking H1 first half 2026 results.
Access the live call here: investors.galderma.com/events-present…
A recording will be available after the event.
#AdvancingDermatology #H1results $GALD

We delivered net sales of 3.134 billion USD in H1, reinforcing our confidence to raise full-year sales guidance.
Read more: galderma.com/news/galderma-…
#AdvancingDermatology #H1results $GALD

New insights from the world’s most extensive skin quality profiling survey highlight the impact of skin concerns and why more personalized treatment approaches matter.
Learn more: galderma.com/news/landmark-…

#SkinSciencebyGalderma #AdvancingDermatology

Galderma receives U.S. FDA approval of Differin® Epiduo® Acne Gel for over-the-counter use, expanding access to a dermatologist-recommended, prescription-strength acne treatment for ages 12+.
Read more: galderma.com/news/galderma-…
#ForUSAudiences
#DifferinEpiduo
#AdvancingDermatology